On 27 June 2006, the European Commission granted a Marketing Authorisation for TYSABRI (natalizumab) as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (MS) to prevent relapses and delay progression of disability. TYSABRI offers new hope for patients living with MS.
Biogen Idec may modify this website and the rules and regulations governing its use, at any time. Modifications will be posted on the website, so please check back when you use the website. By continuing use of the website after such changes are posted you will be accepting such changes.